Novel vaccination strategies against tuberculosis
P Andersen, SHE Kaufmann - Cold Spring …, 2014 - perspectivesinmedicine.cshlp.org
The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG
(Bacillus Calmette–Guérin) vaccine. Novel vaccination strategies are urgently needed to …
(Bacillus Calmette–Guérin) vaccine. Novel vaccination strategies are urgently needed to …
The current status, challenges, and future developments of new tuberculosis vaccines
W Gong, Y Liang, X Wu - Human vaccines & immunotherapeutics, 2018 - Taylor & Francis
Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of
death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain …
death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain …
[HTML][HTML] Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans
M Jeyanathan, DK Fritz, S Afkhami, E Aguirre… - JCI insight, 2022 - ncbi.nlm.nih.gov
Background Adenovirus-vectored (Ad-vectored) vaccines are typically administered via im
injection to humans and are incapable of inducing respiratory mucosal immunity. However …
injection to humans and are incapable of inducing respiratory mucosal immunity. However …
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised …
I Satti, J Meyer, SA Harris, ZRM Thomas… - The Lancet Infectious …, 2014 - thelancet.com
Summary Background Intradermal MVA85A, a candidate vaccine against tuberculosis,
induces high amounts of Ag85A-specific CD4 T cells in adults who have already received …
induces high amounts of Ag85A-specific CD4 T cells in adults who have already received …
Intranasal delivery of MVA vector vaccine induces effective pulmonary immunity against SARS-CoV-2 in rodents
Antigen-specific tissue-resident memory T cells (Trms) and neutralizing IgA antibodies
provide the most effective protection of the lungs from viral infections. To induce those …
provide the most effective protection of the lungs from viral infections. To induce those …
Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines
M Schito, GB Migliori, HA Fletcher… - Clinical infectious …, 2015 - academic.oup.com
Despite concerted efforts over the past 2 decades at developing new diagnostics, drugs, and
vaccines with expanding pipelines, tuberculosis remains a global emergency. Several novel …
vaccines with expanding pipelines, tuberculosis remains a global emergency. Several novel …
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from …
P Pérez, D Astorgano, G Albericio, S Flores… - Frontiers in …, 2022 - frontiersin.org
Current coronavirus disease-19 (COVID-19) vaccines are administered by the intramuscular
route, but this vaccine administration failed to prevent severe acute respiratory syndrome …
route, but this vaccine administration failed to prevent severe acute respiratory syndrome …
Chronic immune activation in TB/HIV co-infection
HIV co-infection is the most critical risk factor for the reactivation of latent tuberculosis (TB)
infection (LTBI). While CD4+ T cell depletion has been considered the major cause of HIV …
infection (LTBI). While CD4+ T cell depletion has been considered the major cause of HIV …
[HTML][HTML] Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails
FAW Verreck, EZ Tchilian, RAW Vervenne… - Tuberculosis, 2017 - Elsevier
M. bovis BCG vaccination against tuberculosis (TB) notoriously displays variable protective
efficacy in different human populations. In non-human primate studies using rhesus …
efficacy in different human populations. In non-human primate studies using rhesus …
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
ZR Manjaly Thomas, I Satti, JL Marshall… - PLoS …, 2019 - journals.plos.org
Background There is an urgent need for an effective tuberculosis (TB) vaccine.
Heterologous prime–boost regimens induce potent cellular immunity. MVA85A is a …
Heterologous prime–boost regimens induce potent cellular immunity. MVA85A is a …